Oncology
Page 1 • 12 itemsGlobal oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
SAKIGAKE Designation Japan: Bispecific Antibodies for Leukemia Status 2026
This article delves into the SAKIGAKE Designation in Japan for bispecific antibodies, focusing on their potential to transform leukemia treatment by 2026.
NMPA Approval Lung Cancer Immunotherapy: PD-1/PD-L1 Combo Trends 2025
This article delves into the NMPA's approval landscape for lung cancer immunotherapy, highlighting the emerging trends of PD-1/PD-L1 combination therapies by 2025.
NMPA Conditional Approval Pathway: Impact on Innovative Oncology Drug Access
The NMPA Conditional Approval Pathway significantly enhances access to innovative oncology drugs, facilitating timely treatment options for cancer patients.
NMPA Priority Review Pathway: Accelerating Innovative Drug Approvals in China
The NMPA Priority Review Pathway accelerates the approval of innovative drugs in China, significantly benefiting patients with critical health needs.
Japanese Bridge Trial Requirements: Key PMDA Regulatory Updates 2024
Stay informed on the key PMDA regulatory updates for Japanese Bridge Trials in 2024, essential for drug XYZ's approval in cancer therapy.
NMPA Approval Trends ADCs: Novel Lung Cancer Therapies in China 2025
Discover the latest NMPA approval trends for antibody-drug conjugates (ADCs) targeting lung cancer in China, focusing on innovative therapies expected by 2025.
NMPA Conditional Approval Pathway: Accelerating Innovative Oncology Drug Access in China
The NMPA Conditional Approval Pathway is transforming access to innovative oncology drugs such as [Drug Name], expediting their availability for patients in China.
NMPA Approval ADCs Lung Cancer: Trends & Clinical Insights 2025
This article delves into the latest NMPA-approved antibody-drug conjugates (ADCs) for lung cancer, examining trends and clinical insights shaping 2025.
CAR-T Cell Therapy Japan: Regulatory Insights & Clinical Trial Landscape
This article delves into CAR-T cell therapy in Japan, highlighting regulatory frameworks and the evolving clinical trial landscape for hematologic malignancies.
![NMPA Approval [Drug Name]: Impact on China’s Oncology Market 2025](/uploads/articles/nmpa-approval-drugname-oncology-market-analysis-2025.webp)
NMPA Approval [Drug Name]: Impact on China’s Oncology Market 2025
The NMPA's approval of Drug Name marks a significant milestone for China's oncology market in 2025, promising enhanced treatment options for cancer patients.
Chinese-Developed ADCs Integration: Clinical Impact & Regulatory Advances in APAC
This article delves into the integration of Chinese-developed antibody-drug conjugates (ADCs) and their significant clinical and regulatory advancements in the APAC region.
APAC KRAS Inhibitors: Elisrasib’s Promise in Advanced NSCLC
Elisrasib emerges as a promising KRAS inhibitor, revolutionizing treatment options for advanced NSCLC in the APAC region.